25 Hydroxyvitamin D and Cytokine Profile in Patients With Relapsing-Remitting Multiple Sclerosis

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Jul 3

PMID 38957253

Authors

Georgi S Slavov

Mariya G Manova

Ivanka I Kostadinova

Affiliations

Soon will be listed here.

Abstract

In experimental allergic encephalomyelitis, the severity of the deficiency is associated with the loss of axons, and it is likely that cytotoxic T-cells 8 (CD8 T) play an important role. In relapsing-remitting multiple sclerosis, there is a correlation between the inflammatory activity in the lesion and the transection of axons. To understand the pathological mechanisms, it is important to evaluate the changes in serum concentrations of pro- and anti-inflammatory cytokines during the disease course. A total of 46 patients and 40 healthy individuals participated in an open-label, prospective, case-control study from 2012 to 2014. The serum concentrations of cytokines were measured using enzyme-linked immunosorbent assay (ELISA). An immune imbalance was observed during relapse and remission phases compared to the control group. During relapse, the levels of interferon-gamma (IFN-γ) were significantly higher compared to those in remission (p=0.017). During remission, there was an improvement in the deficiency (p<0.001), and the anti-inflammatory cytokines transforming growth factor-beta (TGF-β) and interleukin 4 (IL4) increased compared to those in relapse (p=0.006; p=0.009). A correlation was found between the serum concentrations of tumor necrosis factor-alpha (TNF-α) and Expanded Disability Status Scale (EDSS) during relapse (correlation coefficient: 0.301; significance (Sig.) (2-tailed 0.042). During the exacerbation, there was a moderate relationship between interleukin 17 (IL17) and 25-hydroxyvitamin D (25(OH)D) (P (p-value (probability value) = 0.02)). TNF-α, IFN-γ, IL17, and TGF-β serum levels are criteria for evaluating immune inflammatory activity during relapse and remission periods.

References

Carbajal K, Mironova Y, Ulrich-Lewis J, Kulkarni D, Grifka-Walk H, Huber A . Th Cell Diversity in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. J Immunol. 2015; 195(6):2552-9. PMC: 4561206. DOI: 10.4049/jimmunol.1501097. View

Bellan M, Andreoli L, Mele C, Sainaghi P, Rigamonti C, Piantoni S . Pathophysiological Role and Therapeutic Implications of Vitamin D in Autoimmunity: Focus on Chronic Autoimmune Diseases. Nutrients. 2020; 12(3). PMC: 7146294. DOI: 10.3390/nu12030789. View

Capone A, Bianco M, Ruocco G, De Bardi M, Battistini L, Ruggieri S . Distinct Expression of Inflammatory Features in T Helper 17 Cells from Multiple Sclerosis Patients. Cells. 2019; 8(6). PMC: 6628300. DOI: 10.3390/cells8060533. View

Neau J, Artaud-Uriot M, Lhomme V, Bounaud J, Lebras F, Boissonnot L . [Vitamin D and multiple sclerosis. A prospective survey of patients of Poitou-Charentes area]. Rev Neurol (Paris). 2010; 167(4):317-23. DOI: 10.1016/j.neurol.2010.10.002. View

Ortiz G, Pacheco-Moises F, Bitzer-Quintero O, Ramirez-Anguiano A, Flores-Alvarado L, Ramirez-Ramirez V . Immunology and oxidative stress in multiple sclerosis: clinical and basic approach. Clin Dev Immunol. 2013; 2013:708659. PMC: 3794553. DOI: 10.1155/2013/708659. View

Bartosik-Psujek H, Psujek M . Vitamin D as an immune modulator in multiple sclerosis. Neurol Neurochir Pol. 2019; 53(2):113-122. DOI: 10.5603/PJNNS.a2019.0015. View

Franciotta D, Zardini E, Bergamaschi R, Andreoni L, Cosi V . Interferon gamma and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment. J Neurol Neurosurg Psychiatry. 2002; 74(1):123-6. PMC: 1738169. DOI: 10.1136/jnnp.74.1.123. View

Sheikh V, Kasapoglu P, Zamani A, Basiri Z, Tahamoli-Roudsari A, Alahgholi-Hajibehzad M . Vitamin D3 inhibits the proliferation of T helper cells, downregulate CD4 T cell cytokines and upregulate inhibitory markers. Hum Immunol. 2018; 79(6):439-445. DOI: 10.1016/j.humimm.2018.03.001. View

Sintzel M, Rametta M, Reder A . Vitamin D and Multiple Sclerosis: A Comprehensive Review. Neurol Ther. 2017; 7(1):59-85. PMC: 5990512. DOI: 10.1007/s40120-017-0086-4. View

10.

Cantorna M, DeLuca H . In vivo upregulation of interleukin-4 is one mechanism underlying the immunoregulatory effects of 1,25-dihydroxyvitamin D(3). Arch Biochem Biophys. 2000; 377(1):135-8. DOI: 10.1006/abbi.2000.1765. View

11.

Golan D, Halhal B, Glass-Marmor L, Staun-Ram E, Rozenberg O, Lavi I . Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurol. 2013; 13:60. PMC: 3691658. DOI: 10.1186/1471-2377-13-60. View

12.

Soilu-Hanninen M, Aivo J, Lindstrom B, Elovaara I, Sumelahti M, Farkkila M . A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012; 83(5):565-71. DOI: 10.1136/jnnp-2011-301876. View

13.

Santos E, Fields R . Regulation of myelination by microglia. Sci Adv. 2021; 7(50):eabk1131. PMC: 8664250. DOI: 10.1126/sciadv.abk1131. View

14.

Hellings N, Gelin G, Medaer R, Bruckers L, Palmers Y, Raus J . Longitudinal study of antimyelin T-cell reactivity in relapsing-remitting multiple sclerosis: association with clinical and MRI activity. J Neuroimmunol. 2002; 126(1-2):143-60. DOI: 10.1016/s0165-5728(02)00052-8. View

15.

Beck J, Rondot P, CATINOT L, FALCOFF E, Kirchner H, Wietzerbin J . Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations?. Acta Neurol Scand. 1988; 78(4):318-23. DOI: 10.1111/j.1600-0404.1988.tb03663.x. View

16.

Munger K, Chitnis T, Ascherio A . Body size and risk of MS in two cohorts of US women. Neurology. 2009; 73(19):1543-50. PMC: 2777074. DOI: 10.1212/WNL.0b013e3181c0d6e0. View

17.

Mosayebi G, Ghazavi A, Ghasami K, Jand Y, Kokhaei P . Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol Invest. 2011; 40(6):627-39. DOI: 10.3109/08820139.2011.573041. View

18.

Smolders J, Torkildsen O, Camu W, Holmoy T . An Update on Vitamin D and Disease Activity in Multiple Sclerosis. CNS Drugs. 2019; 33(12):1187-1199. PMC: 6890630. DOI: 10.1007/s40263-019-00674-8. View

19.

Mokry L, Ross S, Ahmad O, Forgetta V, Davey Smith G, Goltzman D . Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. PLoS Med. 2015; 12(8):e1001866. PMC: 4549308. DOI: 10.1371/journal.pmed.1001866. View

20.

Lysandropoulos A, Jaquiery E, Jilek S, Pantaleo G, Schluep M, Du Pasquier R . Vitamin D has a direct immunomodulatory effect on CD8+ T cells of patients with early multiple sclerosis and healthy control subjects. J Neuroimmunol. 2010; 233(1-2):240-4. DOI: 10.1016/j.jneuroim.2010.11.008. View